ERBB2 and breast cancer: To further investigate the prognosis–related factors in the neoadjuvant therapy population, DFS multifactorial survival analysis was performed on the non–pCR population of luminal B (HER–2 negative) breast cancer who underwent neoadjuvant therapy.